In the future, revealing the functional interaction of YBX1 with other sEV protein cargoes is vital to further understanding the BM‐MSCs osteoblastic differentiation blockage in AML, thereby enabling us to develop novel therapeutics for paediatric AML. The gene discussed is YBX1; the disease is acute myeloid leukemia.